Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
'Targeted' drugs may be effective against lung and colorectal tumors driven by novel gene abnormalities

'Targeted' drugs may be effective against lung and colorectal tumors driven by novel gene abnormalities

Three new targeted drugs can lead to fatal cancer complications

Three new targeted drugs can lead to fatal cancer complications

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

Inlyta receives FDA approval for treatment of advanced kidney cancer

Inlyta receives FDA approval for treatment of advanced kidney cancer

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Survey reveals high interest in Xalkori among medical oncologists

Survey reveals high interest in Xalkori among medical oncologists

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

AACR, IASLC sponsor conference on molecular origins of lung cancer

AACR, IASLC sponsor conference on molecular origins of lung cancer

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

AVEO third quarter net loss increases to $23.8 million

AVEO third quarter net loss increases to $23.8 million

Combination therapy improves outcomes for liver cancer patients: Study

Combination therapy improves outcomes for liver cancer patients: Study

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.